She may have questions about moderate to severe vasomotor symptoms

But she may not know to ask about her bone health 

Limitation of Use 
When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and non-estrogen medication should be carefully considered.

Women have more than twice the risk of fracture after menopause as they have during the premenopausal and perimenopausal phases; this risk continues to increase as they age.1a 

1. Banks E, Reeves GK, Beral V, et al. Hip fracture incidence in relation to age, menopausal status, and age at menopause: prospective analysis. PLoS Medicine. 2009;6(11):e1000181. 

aBased on The Million Women Study, a large national prospective study that recruited 1.3 million middle-aged women from the National Health Service (NHS) breast screening clinics in England and Scotland between 1996 and 2001, with follow-ups between 1999 and 2004. The study describes the incidence of hip fracture in relationship to age, menopausal status, and age at menopause in 561,609 women who had never used hormone replacement therapy.1

Your patients may not realize that their bones may be weakening.

Only a bone scan can confirm that. But if your patients are at significant risk, Climara Pro® can help prevent postmenopausal osteoporosis.

Meet Stephanie

  • Postmenopausal at the age of 57 years
  • Looking for an option to manage her moderate to severe vasomotor symptoms and help prevent future bone loss
  • Mother had osteoporosis and suffered a hip fracture at the age of 72 years
  • Has an intact uterus

Hypothetical patient for illustrative purposes only. 

Patient profile Stephanie

Stephanie has been postmenopausal for about 2 years and is seeking relief from her increasing number of daily moderate to severe hot flushes. 

 

During a recent visit with her healthcare provider, she complained of an increase in the number of her daily hot flushes and mentioned her mother’s history of osteoporosis, as well as a hip fracture that her mother experienced in her early 70s. She is looking for a treatment that may manage her condition and help prevent postmenopausal osteoporosis.

Review clinical data on a treatment option below.

Patient profile Stephanie

Meet Stephanie

  • Postmenopausal at the age of 57 years
  • Looking for an option to manage her moderate to severe vasomotor symptoms and help prevent future bone loss
  • Mother had osteoporosis and suffered a hip fracture at the age of 72 years
  • Has an intact uterus

Hypothetical patient for illustrative purposes only. 

Stephanie has been postmenopausal for about 2 years and is seeking relief from her increasing number of daily moderate to severe hot flushes. 

 

During a recent visit with her healthcare provider, she complained of an increase in the number of her daily hot flushes and mentioned her mother’s history of osteoporosis, as well as a hip fracture that her mother experienced in her early 70s. She is looking for a treatment that may manage her condition and help prevent postmenopausal osteoporosis.

Review clinical data on a treatment option below.

Bone mineral density (BMD) was significantly increased in both the hip and lumbar spine with 4.4 mg E2 (the estradiol dose in Climara Pro®) compared with placebo

 

The effects of BMD were studied in a randomized, double-blind, placebo-controlled clinical trial in 154 postmenopausal women with hysterectomies (mean age 51.4 years). Patients received calcium supplements if they appeared deficient on a questionnaire. Participants were randomized to receive weekly patches containing 2.2 mg estradiol, 4.4 mg estradiol, or placebo for 728 days of continuous treatment (a total of 26 28-day cycles). Only the results for the estradiol dose in Climara Pro® (4.4 mg E2) and for placebo are presented.

 

BMD increase in lumbar spine and hip charts

aLOCF=last observation carried forward.

Limitation of Use

When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and non-estrogen medication should be carefully considered.

BMD increased at the lumbar spine over a 2-year treatment period (4.4 mg E2 [estradiol dose of Climara Pro®] compared with placebo)

BMD increase in lumbar spine over 2 years chart

 

bData in the figure are for 21 patients on 4.4 mg E2 and 27 placebo patients who completed the study; approximately 44% of randomized patients.

Hand holding climara pro patch

For your appropriate patients:

Prescribe Climara Pro® today!

Explore savings and resources for you and your patients. 

Help your patients save